Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab dose-finding for hyperglycemia in metformin-treated type 2 diabetes
jRCT2080220799Phase 3
- Sponsor
- Novartis
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and hyperglycemia comparing Canakinumab arm with Placebo arm (2 arms).
02
Drugs
canakinumab
03
Conditions
type 2 diabetes mellitus (T2DM)hyperglycemia
Beyond the preview
Go deeper on jRCT2080220799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220799.